2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)

Singapore 09 December 2025 - 11 December 2025

CGM in diabetes: From evidence to practice

06 Feb 2026 by

Continuous glucose monitoring (CGM) is transforming diabetes care in both type 1 diabetes (T1D) and type 2 diabetes (T2D), with or without insulin use, said Dr Pratik Choudhary, Honorary Consultant and Professor at the University of Leicester, UK, during an Abbott-sponsored symposium at ATTD-Asia 2025 in Singapore.

06 Feb 2026

Tirzepatide delivers real-world benefits, safety in T2D patients in India

08 Jan 2026 by

A real-world assessment of tirzepatide in Indian clinical practice has shown significant glycaemic and weight benefits in adults with type 2 diabetes (T2D). The medication is also well tolerated, with manageable gastrointestinal side effects, and highly accepted by patients.

08 Jan 2026

Multidrug combos provide optimal glycaemic control in T2D patients

24 Dec 2025 by

A real-world study from India shows that multiple drug combinations effectively controlled blood sugar levels in individuals with type 2 diabetes (T2D).

24 Dec 2025

Inhaled Technosphere insulin lowers HbA1c in Indian patients with T2D

24 Dec 2025 by

Inhaled Technosphere insulin significantly reduced HbA_1c levels in Indian individuals with type 2 diabetes (T2D) compared with placebo, according to a study presented at ATTD-ASIA 2025.

24 Dec 2025

Oversleeping, late bedtime detrimental in GDM

23 Dec 2025 by

In pregnant women with gestational diabetes mellitus (GDM), prolonged sleep duration and late bedtime may adversely affect glycaemic control and increase the risk of hypoglycaemia, respectively, according to two studies.

23 Dec 2025

Insulin glargine improves glycaemic control in T2D patients in India

22 Dec 2025 by

Findings from the prospective PRIMARY-INDIA study presented at ATTD-Asia 2025 show clinically meaningful improvements in glycaemic control with insulin glargine in individuals with type 2 diabetes (T2D) in primary care settings, with a consistent safety profile.

22 Dec 2025

Insulin glargine/lixisenatide enhances T2DM control in real world

21 Dec 2025 by

Switching to insulin glargine/lixisenatide effectively lowers glucose levels in overweight adults with uncontrolled type 2 diabetes mellitus (T2DM), according to real-world data.

21 Dec 2025

Insulin glargine plus lixisenatide improves outcomes in Chinese adults with T2D

17 Dec 2025 by

Treatment with iGlarLixi* resulted in better clinical outcomes than IDegAsp** in Chinese adults with type 2 diabetes (T2D), regardless of age or disease duration at baseline, according to a post hoc analysis of the phase III Soli-D study presented at ATTD-ASIA 2025.

17 Dec 2025